Questionable efficacy of the rVSV-ZEBOV Ebola vaccine - Authors' reply
Lancet
.
2018 Mar 17;391(10125):1021-1022.
doi: 10.1016/S0140-6736(18)30559-2.
Epub 2018 Mar 15.
Authors
Ira M Longini
1
,
John-Arne Røttingen
2
,
Marie Paule Kieny
3
,
W John Edmunds
4
,
Ana Maria Henao-Restrepo
5
Affiliations
1
Department of Biostatistics, University of Florida, Gainesville, FL, USA.
2
Research Council of Norway, Lysaker, Norway; Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA.
3
Inserm, Paris, France.
4
Faculty of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, UK.
5
WHO, 1211 Geneva 27, Switzerland. Electronic address: henaorestrepoa@who.int.
PMID:
29565012
DOI:
10.1016/S0140-6736(18)30559-2
No abstract available
Publication types
Letter
Comment
MeSH terms
Ebola Vaccines*
Ebolavirus / immunology
Hemorrhagic Fever, Ebola*
Humans
Substances
Ebola Vaccines
Grants and funding
001/WHO_/World Health Organization/International